Intravesical epirubicin chemotherapy: procedure-specific information

What is the evidence base for this information?
This leaflet includes advice from consensus panels, the British Association of Urological Surgeons, the Department of Health and evidence-based sources; it is, therefore, a reflection of best practice in the UK. It is intended to supplement any advice you may already have been given by your GP or other healthcare professionals. Alternative treatments are outlined below and can be discussed in more detail with your Urologist or Specialist Nurse.

What does the procedure involve?
Instillations of Epirubicin into the bladder for aggressive, multiple or recurrent superficial cancer of the bladder

What are the alternatives to this procedure?
Repeated cystoscopy, radiotherapy, surgical removal of the bladder with urinary diversion or bladder reconstruction, systemic chemotherapy

What should I expect before the procedure?
Your Consultant Urologist has referred you for treatment of your superficial bladder cancer. Superficial bladder cancer affects a few layers of cells on the inner surface of the bladder only but has the ability to progress to more aggressive disease If not treated effectively.

The aim of the treatment, therefore, is to stop or slow down re-growth by instilling a drug into the bladder; this is called intravesical chemotherapy.

You will be asked to come to the hospital once a week for 8 weeks. You should limit your fluid input for 6 hours before each treatment.
Your first treatment will take up to 90 minutes. On arrival in the clinic, you will be asked to pass urine which will be tested to ensure that you do not have an infection in the urine. If you do, your treatment will need to be postponed for one week while you are treated with antibiotics. Please be sure to inform your Urologist in advance of your surgery if you have any of the following:

- an artificial heart valve
- a coronary artery stent
- a heart pacemaker or defibrillator
- an artificial joint
- an artificial blood vessel graft
- a neurosurgical shunt
- any other implanted foreign body
- a prescription for Warfarin, Aspirin or Clopidogrel (Plavix®)
- a previous or current MRSA infection
- high risk of variant CJD (if you have received a corneal transplant, a neurosurgical dural transplant or previous injections of human-derived growth hormone)

What happens during the procedure?
A fine plastic tube (called a catheter) will be passed into the bladder and the medication (approximately half a cup of fluid) will be given through it. The catheter will then be removed. You will be asked not to pass urine for an hour to allow the medication to treat the bladder lining.

On your first visit, you will be asked to stay in the clinic for the duration of the treatment and you will be asked to pass urine before you go home. For the remaining treatments, If you live within 20 minutes of the hospital and have your own transport, you may be allowed to go home with the medication in your bladder and pass urine after two hours.

What happens immediately after the procedure?
Once the treatment has been completed, you will be able to go home. You will need to ensure that you have a supply of household bleach at home, since you must pour a cupful of this into the toilet, leaving it for 15 minutes before flushing. You should continue doing this every time you pass urine for the next 24 hours. There is no risk of contamination.

You should drink plenty of fluids (2-3 litres) for the few days after the treatment.

Are there any side-effects?
Most procedures have a potential for side-effects. You should be reassured that, although all these complications are well-recognised, the majority of patients do not suffer any problems after a urological procedure.

Please use the check boxes to tick off individual items when you are happy that they have been discussed to your satisfaction:
Common (greater than 1 in 10)
- Some bladder discomfort after treatment
- Flu-like symptoms which can persist for 2-3 days
- Discoloured urine
- Blood in the urine
- Debris in the urine

Occasional (between 1 in 10 and 1 in 50)
- Skin rash
- Failure to complete the course of treatment due to bladder discomfort
- Urinary tract infection
- Stricture of the urethra (water pipe) following repeated use of a catheter

Rare (less than 1 in 50)
- Severe pain on instillation, persisting afterwards
- Allergic reaction to the instilled chemicals, requiring discontinuation of the treatment
- Stricture of the urethra (water pipe) following use of a catheter

Hospital-acquired infection (overall risk for Addenbrooke’s)
- Colonisation with MRSA (0.02%, 1 in 5,000)
- Clostridium difficile bowel infection (0.04%; 1 in 2,500)
- MRSA bloodstream infection (0.01%; 1 in 10,000)

(These rates may be greater in high-risk patients e.g. with long-term drainage tubes, after removal of the bladder for cancer, after previous infections, after prolonged hospitalisation or after multiple admissions)

What should I expect when I get home?
If you think you have a urine infection (i.e. pain on passing urine, frequency or foul-smelling urine), it is important to contact your GP and get treatment with antibiotics.

What else should I look out for?
Because this treatment is put directly into the bladder and not into the bloodstream, you will not experience the side-effects often associated with other cancer drug treatments.

Are there any other important points?
You should wash your hands and genitals after you have passed urine and it is advisable to bring a wash bag with you to Hospital when you come for the treatment.

You are advised not to have sexual intercourse for at least 24 hours after the treatment as this can cause some discomfort.
If you are a smoker, we will encourage you to stop since smoking seems to encourage recurrence of bladder cancer.

**Driving after surgery**

It is your responsibility to ensure that you are fit to drive following your surgery. You do not normally need to notify the DVLA unless you have a medical condition that will last for longer than 3 months after your surgery and may affect your ability to drive. You should, however, check with your insurance company before returning to driving. Your doctors will be happy to provide you with advice on request.

**Is there any research being carried out in this field at Addenbrooke’s Hospital?**

There is no specific research in this area at the moment but all operative procedures performed in the department are subject to rigorous audit at a monthly Audit & Clinical Governance meeting.

**Who can I contact for more help or information?**

**Oncology Nurses**

- Uro-Oncology Nurse Specialist
  01223 586748
- Bladder cancer Nurse Practitioner (haematuria, chemotherapy & BCG)
  01223 274608
- Prostate cancer Nurse Practitioner
  01223 247608 or 216897 or bleep 154-548
- Surgical Care Practitioner
  01223 348590 or 256157 or bleep 154-134

**Non-Oncology Nurses**

- Urology Nurse Practitioner (incontinence, urodynamics, catheter patients)
  01223 274608 or 586748
- Urology Nurse Practitioner (stoma care)
  01223 349800

**Patient Advice & Liaison Centre (PALS)**

- Telephone
  +44 (0)1223 216756 or 257257
  +44 (0)1223 274432 or 274431
- PatientLine
  *801 (from patient bedside telephones only)
- E mail
  pals@addenbrookes.nhs.uk
- Mail
  PALS, Box No 53
  Addenbrooke's Hospital
  Hills Road, Cambridge, CB2 2QQ
Chaplaincy and Multi-Faith Community

- Telephone
  +44 (0)1223 217769
- Email
derek.fraser@addenbrookes.nhs.uk
- Mail
  The Chaplaincy, Box No 105
  Addenbrooke's Hospital
  Hills Road, Cambridge, CB2 2QQ

MINICOM System ("type" system for the hard of hearing)

- Telephone
  +44 (0)1223 274604

Access Office (travel, parking & security information)

- Telephone
  +44 (0)1223 586969

What should I do with this form?

Thank you for taking the trouble to read this information sheet. If you wish to sign it and retain a copy for your own records, please do so below.

If you would like a copy of this form to be filed in your hospital records for future reference, please let your Urologist or Specialist Nurse know. If you do, however, decide to proceed with the scheduled procedure, you will be asked to sign a separate consent form which will be filed in your hospital notes and you will, in addition, be provided with a copy of the form if you wish.

I have read this information sheet and I accept the information it provides.

Signature……………………………….…………… Date………………………………

How can I get information in alternative formats?

Please ask if you require this information in other languages, large print or audio format: 01223 216032 or patient.information@addenbrookes.nhs.uk

Polish

Informacje te można otrzymać w innych językach, w wersji dużym drukiem lub audio. Zamówienia prosimy składać pod numerem: 01223 216032 lub wysyłając e-mail: patient.information@addenbrookes.nhs.uk

Portuguese

Se precisar desta informação num outro idioma, em impressão de letras grandes ou formato áudio por favor telefone para o 01223
Addenbrooke’s is smoke-free. You cannot smoke anywhere on the site. Smoking increases the severity of some urological diseases and increases the risk of post-operative complications. For advice on quitting, contact your GP or the NHS smoking helpline free on 0800 169 0 169

Document history
Author(s) Nikesh Thiruchelvam (on behalf of the Consultant Urologists)
Department Department of Urology, Box No 43
Addenbrooke’s Hospital
Cambridge University Hospitals NHS Foundation Trust
Hills Road
Cambridge, CB2 2QQ
www.addenbrookes.org.uk
Contact number 01223 216575
Fax number 01223 216069
Dept website www.camurology.org.uk
First published May 2005
Review date April 2014
File name Intravesical epirubicin chemotherapy
Version number 5.0
Ref 100/Urol_04_11